
    
      To evaluate the safety and the dose-response of ASP1517 on Hemoglobin (Hb) correction in the
      treatment of anemia in non-dialysis Chronic Kidney Disease (CKD) patients when ASP1517 is
      applied intermittently. Patients will receive ASP1517 three times a week (TIW) for first
      6weeks. Patients may have the second-randomization to TIW dosing or once-a-week (QW) dosing
      at Week 6, 8, 10, 12, 14 or 16 if patients meet the criteria.
    
  